Anti-Human CSF2 Recombinant Antibody (Namilumab) (CAT#: TAB-259)

Figure 1 The dose-normalized geometric mean plasma concentration–time profiles are shown.

Dose-normalized geometric mean plasma concentration–time profile of namilumab (error bars show ± 1 SD). SD standard deviation.

Huizinga, T. W. J., Batalov, A., Stoilov, R., Lloyd, E., Wagner, T., Saurigny, D., ... & Esfandiari, E. (2017). Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis. Arthritis research & therapy, 19(1), 53.

Figure 2 Potent in vitro neutralization of GM-CSF by a combination of three antibodies.

A fixed amount of GM-CSF (final concentration 50 pg ml−1) was incubated with serial dilutions of one or more antibodies, added to TF-1 cells (10,000 per well), and cell proliferation was measured on day 3 by thymidine incorporation. (a) IC90 values of polyclonal IgG and affinity-purified polyclonal antibodies isolated from the serum of five PAP patients. The numbers indicate the percentage of anti-GM-CSF antibodies relative to total IgG. (b) Serial dilutions of single monoclonal antibodies or mixtures of two and three non-cross-competing antibodies were tested for their capacity to neutralize GM-CSF. (c) The sensitivity of the test was changed by varying the number of cells and the concentration of GM-CSF as indicated. Shown is for each experimental condition the inhibition obtained using single antibodies or a combination of three non-cross-competing antibodies.

Piccoli, L., Campo, I., Fregni, C. S., Rodriguez, B. M. F., Minola, A., Sallusto, F., ... & Lanzavecchia, A. (2015). Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis. Nature communications, 6, 7375.